Clearmind Medicine Enrolls First Patient in Alcohol Use Disorder Trial
Ticker: CMND · Form: 6-K · Filed: Jun 5, 2025 · CIK: 1892500
Sentiment: neutral
Topics: clinical-trial, healthcare, drug-development
TL;DR
Clearmind Medicine just enrolled its first patient in a Phase I/IIa trial for alcohol use disorder. Big step for their drug pipeline.
AI Summary
Clearmind Medicine Inc. announced on June 5, 2025, that it has enrolled the first patient in its Phase I/IIa clinical trial for a treatment targeting Alcohol Use Disorder. This milestone is a significant step in the company's development of novel therapeutics.
Why It Matters
This enrollment marks a critical advancement in the clinical development of Clearmind's potential treatment for Alcohol Use Disorder, a condition affecting millions worldwide.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant and developer of the treatment
- June 5, 2025 (date) — Date of the press release and announcement
- Alcohol Use Disorder (condition) — The target condition for the clinical trial
- Phase I/IIa (trial_phase) — The stage of the clinical trial
FAQ
What is the primary purpose of the Phase I/IIa clinical trial announced by Clearmind Medicine?
The trial is for a treatment targeting Alcohol Use Disorder.
When was the announcement regarding the first patient enrollment made?
The announcement was made on June 5, 2025.
What is the name of the company filing this report?
The company is Clearmind Medicine Inc.
What form is Clearmind Medicine Inc. filing with the SEC?
Clearmind Medicine Inc. is filing a Form 6-K.
What is the Commission file number for Clearmind Medicine Inc.'s SEC filings?
The Commission file number is 001-41557.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 5, 2025 regarding Clearmind Medicine Inc. (CMND).